Giada Rossini1, Paolo Gaibani2, Caterina Vocale2, Roberto Cagarelli3, Maria Paola Landini2. 1. Unit of Microbiology, Regional Reference Centre for Microbiological Emergencies (CRREM), St Orsola Malpighi Hospital, Bologna, Italy. Electronic address: giada.rossini@unibo.it. 2. Unit of Microbiology, Regional Reference Centre for Microbiological Emergencies (CRREM), St Orsola Malpighi Hospital, Bologna, Italy. 3. Regional Health Authority, Emilia-Romagna Region, Bologna, Italy.
Abstract
OBJECTIVES: The capability to detect ZIKV RNA is of crucial importance for cases confirmation. However, due to the short-lived viremia, the detection of ZIKV RNA in plasma/serum is challenging for samples collected more than one week after onset of clinical illness. We compared the window time and detection rate of ZIKV RNA in different specimen types (plasma, whole blood and urine) collected simultaneously at several times post-symptom onset. METHODS: We examined the presence of ZIKV RNA in matched specimens of whole blood, plasma and urine collected in the same date (3-28 days after symptom onset) from 10 ZIKV infected patients. RESULTS: ZIKV RNA was found in plasma as late as 10 days after symptoms onset and tested positive in all 5 (100%) and in 2 of 6 (33,3%) plasma samples collected 1-5 and 6-10 days after symptoms onset, respectively. ZIKV RNA was positive in urine through the 21st day after symptom onset; the detection rate of ZIKV RNA in urine samples was 100% (11/11) for samples collected 1-10 days from symptoms onset, decreasing at later times of sampling. The detection rate of ZIKV RNA in whole blood was comparable to that in urine samples but extended the window of detection of ZIKV RNA up to 26 days after symptom onset. CONCLUSIONS: Our results highlight the usefulness of simultaneously testing multiple specimen types in order to extend the rate and the time frame of ZIKV RNA detection, increasing the possibility of cases confirmation through direct diagnosis in convalescence-phase of infection, supplementing serological data which are often difficult to interpret.
OBJECTIVES: The capability to detect ZIKV RNA is of crucial importance for cases confirmation. However, due to the short-lived viremia, the detection of ZIKV RNA in plasma/serum is challenging for samples collected more than one week after onset of clinical illness. We compared the window time and detection rate of ZIKV RNA in different specimen types (plasma, whole blood and urine) collected simultaneously at several times post-symptom onset. METHODS: We examined the presence of ZIKV RNA in matched specimens of whole blood, plasma and urine collected in the same date (3-28 days after symptom onset) from 10 ZIKVinfectedpatients. RESULTS:ZIKV RNA was found in plasma as late as 10 days after symptoms onset and tested positive in all 5 (100%) and in 2 of 6 (33,3%) plasma samples collected 1-5 and 6-10 days after symptoms onset, respectively. ZIKV RNA was positive in urine through the 21st day after symptom onset; the detection rate of ZIKV RNA in urine samples was 100% (11/11) for samples collected 1-10 days from symptoms onset, decreasing at later times of sampling. The detection rate of ZIKV RNA in whole blood was comparable to that in urine samples but extended the window of detection of ZIKV RNA up to 26 days after symptom onset. CONCLUSIONS: Our results highlight the usefulness of simultaneously testing multiple specimen types in order to extend the rate and the time frame of ZIKV RNA detection, increasing the possibility of cases confirmation through direct diagnosis in convalescence-phase of infection, supplementing serological data which are often difficult to interpret.
Authors: Pritimoy Das; Hossain M S Sazzad; Mohammad Abdul Aleem; M Ziaur Rahman; Mahmudur Rahman; Simon J Anthony; W Ian Lipkin; Emily S Gurley; Stephen P Luby; John J Openshaw Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-08-12 Impact factor: 6.237
Authors: Danielle B L Oliveira; Giuliana S Durigon; Érica A Mendes; Jason T Ladner; Robert Andreata-Santos; Danielle B Araujo; Viviane F Botosso; Nicholas D Paola; Daniel F L Neto; Marielton P Cunha; Carla T Braconi; Rúbens P S Alves; Monica R Jesus; Lennon R Pereira; Stella R Melo; Flávio S Mesquita; Vanessa B Silveira; Luciano M Thomazelli; Silvana R Favoretto; Franciane B Almonfrey; Regina C R M Abdulkader; Joel M Gabrili; Denise V Tambourgi; Sérgio F Oliveira; Karla Prieto; Michael R Wiley; Luís C S Ferreira; Marcos V Silva; Gustavo F Palacios; Paolo M A Zanotto; Edison L Durigon Journal: Viruses Date: 2018-11-07 Impact factor: 5.048
Authors: Jolanda J C Voermans; Suzan D Pas; Anne van der Linden; Corine GeurtsvanKessel; Marion Koopmans; Annemiek van der Eijk; Chantal B E M Reusken Journal: Emerg Infect Dis Date: 2019-07-17 Impact factor: 6.883
Authors: Nadina I Vasileva Wand; Laura C Bonney; Robert J Watson; Victoria Graham; Roger Hewson Journal: J Gen Virol Date: 2018-06-13 Impact factor: 3.891